logo transparent gif
top_white_spacer
Home Latest Stock Forum Topics MyCorner - Personal Stocks Porfolio Stock Lists Investor Insights Investor Research & Links Dynamic Stock Charting FREE Registration About Us top spacer top spacer
 User Password Auto-Login
Enter Stock
 
righttip
branding

Back
First   < Newer   6721-6740 of 7131   Older>   Last  
Latest Forum Topics / IX Biopharma    Last:0.355    +0.01  Post Reply
COMFORT DELGRO - MOVING FORWARD
seanpent
Supreme
14-Sep-2020 09:56     
 
seanpent About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		just checking .... this one China side got any listing ?   

SmallSmall      ( Date: 13-Sep-2020 19:37) Posted:

This is the deal that will be the game changer. Hopes Yiling Pharmaceutical gets the approval soon. It' s been 5 months since the tie up was announced. Don' t see why they would not get the approval as Viagra is widely accepted drug.

IX BIOPHARMA: Stock jumps on China deal for erectile dysfunction drug

Written by  The NextInsight Team
  Published: 27 April 2020
 
 
 
 
The share price of Singapore-listed specialty pharmaceutical company iX Biopharma jumped as much as 35% to touch 27 cents this morning after it announced a licensing deal in China. (Update: The stock closed today +64% at 32.5 cents).
 

RMB700-800m sales?



wafesil

&ldquo Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million.&rdquo

-- iX Biopharma
The agreement with Yiling Pharmaceutical Ltd is for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

Yiling, with reported  revenue of RMB 4.81 billion in 2018, is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd., a public company listed on the Shenzhen Stock Exchange.

Shijiazhuang Yiling Pharmaceutical  has been designated a national key high-tech enterprise in the top 20 China pharma list.



Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China.

iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties.

The initial term of the agreement is 10 years.
 

iX Biopharma stock price 

26 c

52-week range

13 &ndash 29 c

Market cap

S$169 m

PE  (ttm)

-

Dividend yield 

-

1-year return

-2%

Shares outstanding

649 m



Source: Bloomberg


Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade .

The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling.

In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China.

By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China.

Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® .

It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe.

Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd, said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo
 
EvanTan7.19Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma  (photo)  said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo  



Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed.

In addition to Wafesil&trade , iX Biopharma said it has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.

 Useful To Me  Not Useful To Me
boyboy61
Supreme
14-Sep-2020 09:25     
 
boyboy61 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		old news, no impact/effect

seanpent      ( Date: 14-Sep-2020 09:14) Posted:

Wow ...... excellent info .....

SmallSmall      ( Date: 13-Sep-2020 19:37) Posted:

This is the deal that will be the game changer. Hopes Yiling Pharmaceutical gets the approval soon. It' s been 5 months since the tie up was announced. Don' t see why they would not get the approval as Viagra is widely accepted drug.

IX BIOPHARMA: Stock jumps on China deal for erectile dysfunction drug

Written by  The NextInsight Team
  Published: 27 April 2020
 
 
 
 
The share price of Singapore-listed specialty pharmaceutical company iX Biopharma jumped as much as 35% to touch 27 cents this morning after it announced a licensing deal in China. (Update: The stock closed today +64% at 32.5 cents).
 

RMB700-800m sales?



wafesil

&ldquo Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million.&rdquo

-- iX Biopharma
The agreement with Yiling Pharmaceutical Ltd is for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

Yiling, with reported  revenue of RMB 4.81 billion in 2018, is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd., a public company listed on the Shenzhen Stock Exchange.

Shijiazhuang Yiling Pharmaceutical  has been designated a national key high-tech enterprise in the top 20 China pharma list.



Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China.

iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties.

The initial term of the agreement is 10 years.
 

iX Biopharma stock price 

26 c

52-week range

13 &ndash 29 c

Market cap

S$169 m

PE  (ttm)

-

Dividend yield 

-

1-year return

-2%

Shares outstanding

649 m



Source: Bloomberg


Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade .

The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling.

In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China.

By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China.

Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® .

It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe.

Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd, said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo
 
EvanTan7.19Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma  (photo)  said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo  



Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed.

In addition to Wafesil&trade , iX Biopharma said it has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.


 Useful To Me  Not Useful To Me


seanpent
Supreme
14-Sep-2020 09:14     
 
seanpent About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Wow ...... excellent info .....

SmallSmall      ( Date: 13-Sep-2020 19:37) Posted:

This is the deal that will be the game changer. Hopes Yiling Pharmaceutical gets the approval soon. It' s been 5 months since the tie up was announced. Don' t see why they would not get the approval as Viagra is widely accepted drug.

IX BIOPHARMA: Stock jumps on China deal for erectile dysfunction drug

Written by  The NextInsight Team
  Published: 27 April 2020
 
 
 
 
The share price of Singapore-listed specialty pharmaceutical company iX Biopharma jumped as much as 35% to touch 27 cents this morning after it announced a licensing deal in China. (Update: The stock closed today +64% at 32.5 cents).
 

RMB700-800m sales?



wafesil

&ldquo Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million.&rdquo

-- iX Biopharma
The agreement with Yiling Pharmaceutical Ltd is for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

Yiling, with reported  revenue of RMB 4.81 billion in 2018, is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd., a public company listed on the Shenzhen Stock Exchange.

Shijiazhuang Yiling Pharmaceutical  has been designated a national key high-tech enterprise in the top 20 China pharma list.



Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China.

iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties.

The initial term of the agreement is 10 years.
 

iX Biopharma stock price 

26 c

52-week range

13 &ndash 29 c

Market cap

S$169 m

PE  (ttm)

-

Dividend yield 

-

1-year return

-2%

Shares outstanding

649 m



Source: Bloomberg


Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade .

The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling.

In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China.

By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China.

Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® .

It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe.

Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd, said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo
 
EvanTan7.19Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma  (photo)  said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo  



Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed.

In addition to Wafesil&trade , iX Biopharma said it has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.

 Useful To Me  Not Useful To Me
guards80
Supreme
13-Sep-2020 20:15     
 
guards80 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Yes very soon. Should see 40cents soon too

SmallSmall      ( Date: 13-Sep-2020 19:37) Posted:

This is the deal that will be the game changer. Hopes Yiling Pharmaceutical gets the approval soon. It' s been 5 months since the tie up was announced. Don' t see why they would not get the approval as Viagra is widely accepted drug.

IX BIOPHARMA: Stock jumps on China deal for erectile dysfunction drug

Written by  The NextInsight Team
  Published: 27 April 2020
 
 
 
 
The share price of Singapore-listed specialty pharmaceutical company iX Biopharma jumped as much as 35% to touch 27 cents this morning after it announced a licensing deal in China. (Update: The stock closed today +64% at 32.5 cents).
 

RMB700-800m sales?



wafesil

&ldquo Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million.&rdquo

-- iX Biopharma
The agreement with Yiling Pharmaceutical Ltd is for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

Yiling, with reported  revenue of RMB 4.81 billion in 2018, is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd., a public company listed on the Shenzhen Stock Exchange.

Shijiazhuang Yiling Pharmaceutical  has been designated a national key high-tech enterprise in the top 20 China pharma list.



Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China.

iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties.

The initial term of the agreement is 10 years.
 

iX Biopharma stock price 

26 c

52-week range

13 &ndash 29 c

Market cap

S$169 m

PE  (ttm)

-

Dividend yield 

-

1-year return

-2%

Shares outstanding

649 m



Source: Bloomberg


Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade .

The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling.

In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China.

By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China.

Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® .

It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe.

Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd, said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo
 
EvanTan7.19Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma  (photo)  said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo  



Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed.

In addition to Wafesil&trade , iX Biopharma said it has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.

 Useful To Me  Not Useful To Me
SmallSmall
Supreme
13-Sep-2020 19:37     
 
SmallSmall About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin

This is the deal that will be the game changer. Hopes Yiling Pharmaceutical gets the approval soon. It' s been 5 months since the tie up was announced. Don' t see why they would not get the approval as Viagra is widely accepted drug.

IX BIOPHARMA: Stock jumps on China deal for erectile dysfunction drug

Written by  The NextInsight Team
  Published: 27 April 2020
 
 
 
 
The share price of Singapore-listed specialty pharmaceutical company iX Biopharma jumped as much as 35% to touch 27 cents this morning after it announced a licensing deal in China. (Update: The stock closed today +64% at 32.5 cents).
 

RMB700-800m sales?



wafesil

&ldquo Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million.&rdquo

-- iX Biopharma
The agreement with Yiling Pharmaceutical Ltd is for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China.

Yiling, with reported  revenue of RMB 4.81 billion in 2018, is a subsidiary of Shijiazhuang Yiling Pharmaceutical Co. Ltd., a public company listed on the Shenzhen Stock Exchange.

Shijiazhuang Yiling Pharmaceutical  has been designated a national key high-tech enterprise in the top 20 China pharma list.



Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China.

iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties.

The initial term of the agreement is 10 years.
 

iX Biopharma stock price 

26 c

52-week range

13 &ndash 29 c

Market cap

S$169 m

PE  (ttm)

-

Dividend yield 

-

1-year return

-2%

Shares outstanding

649 m



Source: Bloomberg


Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade .

The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling.

In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China.

By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China.

Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® .

It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe.

Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd, said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo
 
EvanTan7.19Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma  (photo)  said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo  



Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed.

In addition to Wafesil&trade , iX Biopharma said it has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets.
 Useful To Me  Not Useful To Me


Superkilat
Elite
13-Sep-2020 12:33     
 
Superkilat About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Have you read up my reply to your PM?  Check it out your inbox!
 Useful To Me  Not Useful To Me
guards80
Supreme
12-Sep-2020 20:06     
 
guards80 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Placement at 0.230 is very good 200MA support those BB must be study this MA action
 Useful To Me  Not Useful To Me
guards80
Supreme
12-Sep-2020 20:05     
 
guards80 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Wont hit 220 liaoz 200MA support 225 and rebound from there is good.

RyantNg      ( Date: 12-Sep-2020 12:17) Posted:

Q at 0.22, nvr get it.

Nvr mind , try again on Monday 0.22 and 02

After that sell at 0.23
 Useful To Me  Not Useful To Me


RyantNg
Senior
12-Sep-2020 12:17     
 
RyantNg About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Q at 0.22, nvr get it.

Nvr mind , try again on Monday 0.22 and 02

After that sell at 0.23
 Useful To Me  Not Useful To Me
seanpent
Supreme
11-Sep-2020 22:06     
 
seanpent About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Ride the reversal ... hope it will head back to 35

guards80      ( Date: 11-Sep-2020 17:41) Posted:

Correction done at 225 now slowly push up. Soon above 30cents again yeah✌

 Useful To Me  Not Useful To Me
guards80
Supreme
11-Sep-2020 17:41     
 
guards80 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Correction done at 225 now slowly push up. Soon above 30cents again yeah✌
 Useful To Me  Not Useful To Me
seanpent
Supreme
11-Sep-2020 14:12     
 
seanpent About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		suppose vaccine still crucial and the key to overcoming this crisis .....
 Useful To Me  Not Useful To Me


seanpent
Supreme
11-Sep-2020 13:47     
 
seanpent About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		great !  learning something today ..... thanks !

SmallSmall      ( Date: 11-Sep-2020 13:45) Posted:

If you follow the technicals, the picture is clearer. RSI rebounding. First rebound level $0.245 I guess :)

seanpent      ( Date: 11-Sep-2020 13:42) Posted:

looks like the direction is bit clearer now ..... now at 235/240 level .....
 Useful To Me  Not Useful To Me
SmallSmall
Supreme
11-Sep-2020 13:45     
 
SmallSmall About Contact  Quote this Post!  
  x 0
  x 1

 Alert Admin 		If you follow the technicals, the picture is clearer. RSI rebounding. First rebound level $0.245 I guess :)

seanpent      ( Date: 11-Sep-2020 13:42) Posted:

looks like the direction is bit clearer now ..... now at 235/240 level .....
 Useful To Me  Not Useful To Me
seanpent
Supreme
11-Sep-2020 13:42     
 
seanpent About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		looks like the direction is bit clearer now ..... now at 235/240 level .....
 Useful To Me  Not Useful To Me
guards80
Supreme
11-Sep-2020 12:58     
 
guards80 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Becoz placement havnt injected in. Now let see any clear direction

easywin      ( Date: 11-Sep-2020 12:32) Posted:

This counter down fast up very slow no good to play 

 Useful To Me  Not Useful To Me
easywin
Supreme
11-Sep-2020 12:32     
 
easywin About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		This counter down fast up very slow no good to play 
 Useful To Me  Not Useful To Me
guards80
Supreme
11-Sep-2020 12:24     
 
guards80 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Bb is collecting low. Let shortseller sell them cheaper.

JessTrang      ( Date: 11-Sep-2020 12:12) Posted:

Making there is more buyer than seller to make it looks nice. Frankly speaking, my average price of this counter is 300. From what I observed, this counter transactions is very suspicious. Everyday the buying volume is higher than the selling but the prices is slowly going down day by day. This doesn' t makes sense.

guards80      ( Date: 11-Sep-2020 11:51) Posted:

Making vol. To push u
 Useful To Me  Not Useful To Me
guards80
Supreme
11-Sep-2020 12:23     
 
guards80 About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		Me 285 300lot ✌

JessTrang      ( Date: 11-Sep-2020 12:12) Posted:

Making there is more buyer than seller to make it looks nice. Frankly speaking, my average price of this counter is 300. From what I observed, this counter transactions is very suspicious. Everyday the buying volume is higher than the selling but the prices is slowly going down day by day. This doesn' t makes sense.

guards80      ( Date: 11-Sep-2020 11:51) Posted:

Making vol. To push u
 Useful To Me  Not Useful To Me
seanpent
Supreme
11-Sep-2020 12:23     
 
seanpent About Contact  Quote this Post!  
  x 0
  x 0

 Alert Admin 		hard to understand for us layman 

zaylatt      ( Date: 11-Sep-2020 12:20) Posted:

this counter is heavily manipulated. 

JessTrang      ( Date: 11-Sep-2020 12:12) Posted:

Making there is more buyer than seller to make it looks nice. Frankly speaking, my average price of this counter is 300. From what I observed, this counter transactions is very suspicious. Everyday the buying volume is higher than the selling but the prices is slowly going down day by day. This doesn' t makes sense
 Useful To Me  Not Useful To Me
                                                         First   < Newer   6721-6740 of 7131   Older>   Last  



ShareJunction Version: 27 Nov 2020 ver- All Rights Reserved. Copyright ShareJunction Pte. Ltd. Disclaimer: All prices from are delayed. ShareJunction does not provide you with any financial advice. We are not into the business of providing any investment advice. See our Terms and Conditions and Privacy Policy of using this website. Data is delayed for varying periods of time depending on the exchange, but for at least 15 minutes. Copyright © SIX Financial Information Ltd. and its licensors. All Rights reserved. Further distribution and use by third parties prohibited. SIX Financial Information and its licensors make no warranty for information displayed and accept no liability for data and prices. SIX Financial Information reserves the right to adapt and/or alter this website at any time without prior notice.

Web design by FoundationFlux. Hosted with Signetique Cloud.